+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit



Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit



Medicare and Medicaid Research Review 4(1)



This study estimates the effects of generic competition, increased cost-sharing, and benefit practices on utilization and spending for prescription drugs. We examined changes in Medicare price and utilization from 2007 to 2009 of all drugs in 28 therapeutic classes. The classes accounted for 80% of Medicare Part D spending in 2009 and included the 6 protected classes and 6 classes with practically no generic competition. All variables were constructed to measure each drug relative to its class at a specific plan sponsor. We estimated that the shift toward generic utilization had cut in half the rate of increase in the price of a prescription during 2007-2009. Specifically, the results showed that (1) rapid generic penetration had significantly held down costs per prescription, (2) copayment and other benefit practices shifted utilization to generics and favored brands, and (3) price increases were generally greater in less competitive classes of drugs. In many ways, Part D was implemented at a fortuitous time; since 2006, there have been relatively few new blockbuster drugs introduced, and many existing high-volume drugs used by beneficiaries were in therapeutic classes with multiple brands and generic alternatives. Under these conditions, our paper showed that plan sponsors have been able to contain costs by encouraging use of generics or drugs offering greater value within therapeutic classes. It is less clear what will happen to future Part D costs if a number of new and effective drugs for beneficiaries enter the market with no real competitors.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053728216

Download citation: RISBibTeXText

PMID: 24918023


Related references

The impact of the Medicare Part D prescription benefit on generic drug use. Journal of General Internal Medicine 23(10): 1673-1678, 2008

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015. JAMA Internal Medicine 178(4): 567-569, 2018

Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions; prescription drug benefit program: payments to sponsors of retiree prescription drug plans. Final rule. Federal Register 77(8): 1877-1883, 2012

Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Services Research 38(4): 1051-1063, 2003

Employer drug benefit plans and spending on prescription drugs. JAMA 288(14): 1733-1739, 2002

The New Medicare Part D Prescription Drug Benefit: An Estimation of Its Effect on Prescription Drug Costs in a Medicare Population with Atrial Fibrillation. Yearbook of Cardiology 2008: 498-499, 2008

The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. Journal of the American Geriatrics Society 55(7): 1038-1043, 2007

Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit. Journal of the American Pharmacists Association 49(1): 18-25, 2009

The impact of the medicare part D prescription drug benefit on prescription utilization and out-of-pocket expenditures. Journal of Investigative Medicine 56(3): 620, 2008

Medicare prescription drugs: a benefit whose time has come. Physician Executive 25(4): 89-90, 1999

The new Medicare prescription drug benefit: important issues for physician practices. Journal of Medical Practice Management 21(3): 133-137, 2006

Demand for a Medicare prescription drug benefit: exploring consumer preferences under a managed competition framework. Inquiry 40(2): 169-183, 2003

Differential take-up of the medicare part D prescription drug benefit. 2008

How the Medicare Part D drug benefit changed the distribution of out-of-pocket pharmacy spending among older beneficiaries. Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 65(4): 502-507, 2010

Medicare modernization: the new prescription drug benefit and redesigned Part B and Part C. Proceedings 19(1): 21-23, 2006